Corporatism and big pharma

Authors

David Stoesz, Kean University
Myra Robinson, Kean University
Yomaira Carrero-Iglesia, Kean University
Desiree Curry, Kean University
Tylencia Selph, Kean University
Rebecca Sidoti, Kean University

Document Type

Article

Publication Date

1-1-2016

Abstract

The pharmaceutical industry has leveraged public policy to its benefit, prohibiting the federal government from discounts on drug prices through bulk purchases while using the tax code to develop Patient Assistance Foundations to claim charitable contributions as well as justifying moving income overseas to reduce tax liability. Consumers and taxpayers are left covering the costs of Big Pharma's corporatism. Regulatory reforms are proposed to make drug companies more socially responsible.

Publication Title

Ethical Human Psychology and Psychiatry

First Page Number

36

Last Page Number

47

DOI

10.1891/1559-4343.18.1.36

Recommended Citation

Stoesz, David; Robinson, Myra; Carrero-Iglesia, Yomaira; Curry, Desiree; Selph, Tylencia; and Sidoti, Rebecca, "Corporatism and big pharma" (2016). Kean Publications. 1785.
https://digitalcommons.kean.edu/keanpublications/1785